Leïla Bengrine-Lefevre

Supplementary Table S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Raw data

Supplementary Figure S3 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S3. Technical control: association between the amount of DNA processed in bisulfite and ddPCR and the number of ALB copies detected.

Supplementary Figure S2 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S2. Plasma volume and extraction yield.

Supplementary Figure S8 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S8. Association between olaparib treatment and survival according to ctDNA clearance, p53 molecular group, nLST, and stage I-III at diagnostic. Kaplan-Meir curves. OLA: olaparib. PLA: placebo. p value as per log-rank test.

Supplementary Figure S6 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S6. Association between ctDNA levels and sample timing. Lines highlight paired samples.

Supplementary Figure S7 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S7. Association between ctDNA detection after chemotherapy and nLST. nLST: number of large-scale transitions as per GIScar (see method – surrogate of homologuous repair deficiency-associated genomic scars)

Supplementary Figure S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S1. Flow overview. ctDNA: circulating tumor DNA. C1-C6 : figure cycle 1 to cycle 6 of first line chemotherapy.

Supplementary Figure S5 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S5. Association between maximal circulating fraction and DNA extraction yield.

Supplementary Figure S4 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S4. Association between circulation of OXT and ZSCAN12. Pearson r = 0.95.

Data from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

AbstractPurpose: ctDNA may offer a noninvasive means to evaluate tumor response and anticipate disease dynamics before radiologic changes in advanced endometrial carcinoma. Experimental Design: This ancillary analysis included patients from the multicenter, randomized, phase II GINECO-UTerin OLAparib (UTOLA) trial (NCT03745950) evaluating olaparib/placebo …

Supplementary Figure S9 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, Alexandra Leary, Aurelia Baures et autres

Figure S9. Association between ctDNA and PFS1. Regression curve fitted as y = log (x).

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, A. Leary, Aurelia Baures et autres

PURPOSE: ctDNA may offer a noninvasive means to evaluate tumor response and anticipate disease dynamics before radiologic changes in advanced endometrial carcinoma. EXPERIMENTAL DESIGN: This ancillary analysis included patients from the multicenter, randomized, phase II GINECO-UTerin OLAparib (UTOLA) trial (NCT03745950) evaluating olaparib/placebo …

fr, in, lu, br (code pays fourni par la source)